[PDF] Top 20 Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
Has 10000 "Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes." found on our website. Below are the top 20 most common "Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.".
Pharmacokinetic Characteristics and Clinical Efficacy of an SGLT2 Inhibitor Plus DPP-4 Inhibitor Combination Therapy in Type 2 Diabetes.
... increase in endogenous glucose production and thereby enhance the glucose-lowering ability of SGLT2i while reducing the risk of ketoacidosis, although this remains to be ...reductions ... Voir le document complet
44
DPP-4 inhibitor plus SGLT-2 inhibitor as combination therapy for type 2 diabetes: from rationale to clinical aspects.
... profile of empagliflozin/linagliptin was similar to the known safety profiles of the individual ...components. In drug-naïve T2D patients, the proportion of subjects with adverse events over ... Voir le document complet
37
DPP-4 inhibitors in the management of type 2 diabetes: A critical review of head-to-head trials.
... instead of < 7% (53 mmol/mol). 3.2.4. Gliptins combined with insulin in type 2 diabetes mellitus Insulin therapy in T2DM patients is frequently initiated while oral ... Voir le document complet
15
The novel TORC1/2 kinase inhibitor PQR620 has anti-tumor activity in lymphomas as a single agent and in combination with venetoclax
... status of BCL2, MYC and TP53 was defined as previously reported [ 28 ...Therapeutics and dissolved in dimethyl sulphoxide (DMSO) to obtain a stock concentration of 10 ...Viability ... Voir le document complet
12
Effects of reducing blood pressure on cardiovascular outcomes and mortality in patients with type 2 diabetes: Focus on SGLT2 inhibitors and EMPA-REG OUTCOME.
... therapies in this respect [65]. Thiazide diuretics, including thiazide-type (chlorothiazide and hydrochlorothiazide) and thiazide-like diuretics (indapamide and chlorthalidone), have ... Voir le document complet
30
Neomycin: An Effective Inhibitor of Jasmonate-Induced Reactions in Plants
... cyt and JA-Ile and also downstream expression of JA-Ile-responsive genes, VSP2 and LOX2 (Vadassery et ...inhibitors of jasmonate-induced responses have already been used in plant ... Voir le document complet
11
Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study.
... J Weiss, Alan J Kivitz, H Jackson Downey, Richard E Mills, James W Snyder, Albert J Razzetri, David J Morin, Paul C Tung, Richard V Albery, Scott D Bleser, Donald L Anderson, Curtis J Mello, Lisa Harris, Gerald E ... Voir le document complet
16
Type 2 diabetes mellitus and osteoarthritis
... baseline and OA outcome during follow up (adjusted HR = ...However, in a case-control study performed in Taiwan, patients who have OA and T2DM receiving combination NSAIDs and ... Voir le document complet
12
Pathophysiology of type 2 diabetes.
... ABSTRACT Type 2 diabetes mellitus is a heterogeneous syndrome characterized by abnormalities in carbohydrate and fat ...causes of type 2 diabetes are multi- ... Voir le document complet
7
Dose-dependent modulation of choroidal neovascularization by plasminogen activator inhibitor type 1: Implications for clinical trials
... strong inhibitor of angiogenesis, 33 was downregulated in older ...report of a dose-dependent PAI-1 effect on angiogenesis in a model related to pathologic conditions of the ... Voir le document complet
10
Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes.
... SR and enalapril treatment were well tolerated in this study, and no new adverse events ...events, in that cough is not usually related to diuretic use, and hyperuricaemia is not ... Voir le document complet
8
Treatment of type 2 diabetes.
... 4. Therapy risk and benefits As the prevalence of type 2 diabetes and the risk of severe side-effects of oral antidiabetic agents are markedly ... Voir le document complet
13
Place des inhibiteurs des SGLT2 dans le traitement du patient diabétique de type 2
... discuté plus haut, sans doute moins de non-répondeurs, tout en recourant à une simple prise orale plutôt qu’à une injection sous-cutanée, et pour un prix journalier nettement ... Voir le document complet
9
Perceptions of insulin therapy in people with type 2 diabetes and physicians: a cross-sectional survey conducted in france
... questions in French request- ing information on demographics and diabetes therapies, and included questions on feelings, perceptions, and fears of insulin ...answers, and ... Voir le document complet
11
Corrosion inhibition of galvanized steel by LDH - inhibitor hybrids : Mechanisms of Inhibitor Release and Corrosion Reactions
... mechanisms of aqueous corrosion, corrosion inhibition and metal dissolution [ 60 , 106 , 154 158 ...One of the major disadvantage of conventional electrochemical meth- ods, it is a ... Voir le document complet
248
Pharmacological prevention of type 2 diabetes.
... event of development of ...risk of developing T2DM irrespective of age, sex, and ...diagnosis of diabetes was based on 2 OGTT as recommended by the Expert Committee ... Voir le document complet
46
Characterization of Torin2, an ATP-Competitive Inhibitor of mTOR, ATM, and ATR
... Department of Biology, Massachusetts Institute of Technology, Cambridge, MA 02139 Abstract mTOR is a highly conserved serine/threonine protein kinase that serves as a central regulator of cell ... Voir le document complet
22
Pharmacokinetic study of a new synthetic MMP inhibitor (Ro 28-2653) after IV and oral administration of cyclodextrin solutions
... cyclodextrins, 2-hydroxypropyl-β-cyclodextrin (HP-β-CD) appears to be especially useful, based on its safety for intravenous administration and on its complexation potential (Bertholet et ...Brewster ... Voir le document complet
10
Anti-invasive, antitumoral, and antiangiogenic efficacy of a pyrimidine-2,4,6-trione derivative, an orally active and selective matrix metalloproteinases inhibitor
... liver of breast carcinomas as well as lymphoma in mice (15, 16). In addition, clinical trials revealed that prolonged treatment with broad-spectrum MMPIs caused musculoskeletal pain and ... Voir le document complet
15
‘Treatment-resistant’ type 2 diabetes: Which definition for clinical practice?
... also of interest to compare treatment-resistant diabetes with so-called ‘Psychological Insulin Resistance’ ...reluctance of healthcare providers to prescribe, and for patients to take, insulin ... Voir le document complet
3
Sujets connexes